SCHEMBL25570261

SCHEMBL25570261

CC(C)CCNC(C)CCC(C)CCNC(=O)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 4/20 0.41
DNPEP Q9ULA0 3/20 0.41
RNPEP Q9H4A4 3/20 0.36
LAP3 P28838 3/20 0.35
RAB9A P51151 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
CYP2C19 P33261 2/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
KMT2A Q03164 1/20 0.34
GAA P10253 1/20 0.34
MAPK1 P28482 2/20 0.34
CAPN9 O14815 2/20 0.34
CAPN1 P07384 1/20 0.34
CTSB P07858 1/20 0.34
NPC1 O15118 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11129 0.82 ANPEP (0.55) ANPEPDNPEPRNPEPLAP3RAB9A
SCHEMBL22055144 0.75 KMT2A (0.38) ANPEPDNPEPCYP2C19CYP2D6CYP2C9
SCHEMBL22600632 0.74 TSHR (0.40) ANPEPDNPEPCYP2C19CYP2D6CYP2C9
SCHEMBL18768475 0.74 LMNA (0.31)
SCHEMBL19915434 0.74 DPP7 (0.47) CYP2C19CYP2D6CYP2C9KMT2A
SCHEMBL20810611 0.72 USP2 (0.46) ANPEPDNPEPCYP2C19CYP2D6CYP2C9
SCHEMBL14076746 0.72 ANPEP (0.42) ANPEPDNPEPLAP3CYP2C19CYP2D6
SCHEMBL13995614 0.71 CYP2D6 (0.33) SMN1; SMN2CYP2D6KMT2A
SCHEMBL11921172 0.70 KMT2A (0.50) ANPEPDNPEPCYP2C19CYP2D6CYP2C9
SCHEMBL24847372 0.69 KMT2A (0.39) ANPEPDNPEPCYP2C19CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167105-A1 BCL-2 PROTEIN INHIBITORS RECURIUM IP HOLDINGS, LLC 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167105-A1 BCL-2 PROTEIN INHIBITORS BCL2, BCL2L1, BCL2L2 ANPEP 2925/4885DNPEP 2208/4885RNPEP 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.